$BURUD NUBURU Issues Shareholder Letter on Strategic

New Post Public Reply Private Reply Replies (0) Message Board
trooperstocks
28
$BURUD NUBURU Issues Shareholder Letter on Strategic Progress and NYSE American Appeal

Executive Chairman and Co-Chief Executive Officer Alessandro Zamboni discusses split-adjusted OTC trading, Tekne closing progress and execution of NUBURU’s dual-use Defense & Security platform

DENVER--(BUSINESS WIRE)--NUBURU, Inc. (OTC Pink: BURUD) ("NUBURU" or the "Company", a next-generation dual-use Defense & Security integrated platform company, today issued the following letter to shareholders from Alessandro Zamboni, Executive Chairman and Co-Chief Executive Officer.

Dear Fellow Shareholders,

NUBURU common stock is expected to begin trading today on a split-adjusted basis on the OTC Pink Market under the temporary symbol “BURUD,” following the 1-for-40 reverse stock split that became effective at 4:30 p.m. Eastern Time on September 1, 2026. The “D” suffix is expected to remain for 20 business days, after which the common stock is expected to resume trading on the OTC Pink Market under its base symbol, “BURU.” The reverse split is a mechanical change: it reduces the number of shares outstanding and proportionately adjusts the per-share reference price, while the market determines the trading price thereafter. Subject to the fractional-share treatment previously disclosed, it does not by itself change a shareholder’s proportional ownership or create economic value.

The reverse split was undertaken to address price-related considerations in the pending NYSE American appeal; it does not ensure compliance or resumption of trading. We believe shareholder value must come from execution: completing the proposed Tekne transaction, integrating complementary capabilities into one platform, converting opportunities into contracts and cash, and strengthening NUBURU’s capital structure.

NYSE American Process

NUBURU’s common stock remains listed on NYSE American under the symbol “BURU” pending completion of the appeal process, although trading on NYSE American remains suspended. The Company is in active dialogue with NYSE Regulation regarding the path to a potential resumption of trading. Any resumption remains subject to NYSE Regulation’s determination and completion of applicable corporate-action notice procedures. No decision has been made, NYSE Regulation has not provided the Company with a specific sustained post-split trading-price threshold or duration for a potential resumption of trading, and there can be no assurance whether or when trading on NYSE American will resume. We will report material developments as they occur.

Tekne: Closing Progress and Industrial Scale

As detailed in our September 1, 2026 release, NUBURU and the other parties are advancing the remaining steps toward the Company’s proposed acquisition of a 70% controlling interest in Tekne S.p.A. following the Italian Government’s Golden Power authorization on August 5, 2026. Based on current progress, NUBURU expects closing during the first half of October 2026, subject to completion of the remaining closing actions.

That release also reported Tekne management’s preliminary, unaudited review of its customer order portfolio, which indicated approximately $135.4 million in adjusted active remaining order value. That figure is management-derived, represents 100% of Tekne, remains subject to NUBURU’s customary closing verification, is not a measure defined under U.S. GAAP and does not represent recognized revenue, guaranteed future revenue, cash collections or financial guidance. It nonetheless provides a measurable operating benchmark against which shareholders can assess conversion into revenue and cash.

Building One Scalable Platform

Upon closing, Tekne is expected to add industrial depth in special vehicles, defense mobility, electronic systems, EW/CEMA and mission-package integration. NUBURU Defense Italy S.r.l. (“NDI”) is intended to coordinate the Group’s Italian activities and serve as an integration and governance hub, and NUBURU has initiated recruitment for a Chief Platform Officer to lead the common technical roadmap, architecture and cross-company productization. Within NDI, the planned Platform Integration and Software Factory, or “Platform Factory,” would be an integration and productization function rather than a separate manufacturing facility.

Our objective is a repeatable, multi-year model combining software licenses and subscriptions; hardware support, maintenance and upgrades; and integration, engineering and lifecycle services. These are strategic objectives, not contracted revenue or financial guidance.

Persistent Readiness and Strategic Alignment

Security requirements increasingly extend across peacetime, crisis and conflict, requiring persistent situational awareness, resilient communications, operational continuity and rapid adaptation. Allied defense and security investment in the United States and Europe is rising against that backdrop, and the August 2026 U.S. National Security Science and Technology Strategy identifies advanced manufacturing and materials, artificial intelligence and autonomy, communications and networking, directed energy, information management and cybersecurity, sensing and signature management, and space technologies among its priority areas. NUBURU believes its dual-use, multi-layer and multi-domain roadmap is directionally aligned with several of these themes. This is the Company’s own assessment and does not constitute government endorsement, qualification, an award, an order or a funding commitment, and our opportunity depends in each case on customer priorities, procurement, competition, funding and execution.

What Shareholders Should Measure

Tekne — closing the proposed transaction, implementing governance, and reporting disciplined conversion of orders into revenue and cash;

Platform execution — forming and operationalizing NDI, recruiting the Chief Platform Officer, advancing the Platform Factory and securing customer validation and contractual awards; and

Financial and capital-markets discipline — liquidity, capital allocation, dilution management and transparent updates regarding the NYSE American appeal.

Thank you for your patience and engagement. We believe NUBURU is assembling a strategically relevant platform as defense, infrastructure and digital-resilience needs converge. We also know that belief does not create value. We ask to be evaluated by milestones, contracts, revenue, cash and disciplined delivery — not by the arithmetic of a reverse split or a single trading day.

Sincerely,

Alessandro Zamboni

Executive Chairman and Co-Chief Executive Officer 

Nuburu Inc. (BURU) Stock Research Links

BURU Board Company Profile Buy Rating Time & Sales News Filings Financials
What I post is my opinion. Do your own DD. Make your own investment decision. Links, images, & retweets are not endorsements.

1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.

4️⃣Not Financial Advice. What I post is my opinion.
Also Paid for Advertising/IR/PR on Emerging Companies
Full Disclaimer: https://corporateads.com/disclaimer/
Scroll down for more posts ▼

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 8

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading

Top 5 Most Recently Viewed Articles

A Comprehensive Look at Apple's Competitive Position in Tech

Updated Category News Views 313

Understanding Apple's Competitive Landscape In today's dynamic business environment, a deep-dive analysis of top companies is essential for investors and industry insiders. This examination will focus on Apple (AAPL), alongside its chief rivals in the Technology Hardware, Storage & Peripherals sector. By analyzing crucial financial indicators, market positioning, and...

Continue Reading
Cegedim Shares Insights on Latest Liquidity Contract Performance

Updated Category News Views 135

Overview of Cegedim's Liquidity Contract Statement This article covers the latest updates on Cegedim’s liquidity contract performance, highlighting significant figures and trends that reflect the company's financial health. Cegedim has established a robust liquidity contract with Rothschild Martin Maurel, aimed at promoting transparency and liquidity in its shares. Key...

Continue Reading
Silexion Therapeutics Advances SIL204 for Pancreatic Cancer

Updated Category News Views 136

Silexion Therapeutics Moves Forward with SIL204 Silexion Therapeutics Corp. (NASDAQ: SLXN) is celebrating a significant milestone with the completion of crucial toxicology studies for its innovative RNA silencing therapy, SIL204. This groundbreaking therapy, designed to target mutated KRAS oncogenes, has shown no signs of systemic organ toxicity, reinforcing the...

Continue Reading
Emerson Partners with LifeSight for Enhanced Pension Solutions

Updated Category News Views 178

Emerson Partners with LifeSight for Pension Solutions LifeSight, WTW’s UK defined contribution (DC) master trust, has stepped into a significant role by becoming the full master trust provider for Emerson, the advanced electronics powerhouse. This partnership aims to cover all active, deferred, and drawdown members effectively, ensuring they are well-accommodated in...

Continue Reading
Howard Marks Joins Alliance for Decision Education Board

Updated Category News Views 227

Exciting News from the Alliance for Decision Education The Alliance for Decision Education is thrilled to announce an important addition to its Board of Directors. Howard Marks, a leader in investment management and a well-respected voice in decision-making, has agreed to join the board. As the co-chairman and co-founder of Oaktree Capital Management, Marks brings with...

Continue Reading